Editorial Comment

The authors provide a retrospective review of a large, prospectively managed database of patients with metastatic renal cell carcinoma in South Korea who received a first line tyrosine kinase inhibitor. In this cohort of more than 1,000 patients the authors found that conditional survival improved with time after initial treatment with the tyrosine kinase inhibitor. This trend was mostly driven by patients with Heng poor risk disease.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Adult Urology Source Type: research